Inivata Raises $52.6M For Liquid Biopsy Commercialization

 
• By Catherine Longworth

Inivata has raised $52.6m to support commercialization of its blood test for non-small cell lung cancer (NSCLC) diagnosis.

Molecule of DNA forming inside the test tube in the blood test equipment.3d rendering,conceptual image. - Image
• Source: shutterstock.com

More from Business

More from Medtech Insight